R&D News | pharmaphorum

News

Nicox plans filings for glaucoma after phase 3 win

Nicox is on track to file for approval of its therapy for eyesight-robbing disease glaucoma in the US and China after a second positive phase 3 trial.

News

Viking felled by dropout rates in oral obesity drug trial

Viking Therapeutics shares slumped on discontinuation rates with its oral obesity drug in a phase 2 trial, but are investors missing the point?

News

Merck has a $2bn flutter on Skyhawk's RNA platform

Merck KGaA has become the latest drugmaker to partner with Skyhawk Therapeutics on its RNA splicing drug discovery engine.

News

Pfizer suffers another hit to its GBT sickle cell portfolio

Pfizer's $5.4 billion takeover of Global Blood Therapeutics three years ago is starting to look like a poor deal.

News

AI could lead to 'golden age' of antibiotics

Generative artificial intelligence could hold the key to turning back the rising tide of antimicrobial resistance, say MIT researchers.

News

Vedanta's microbiome therapy for IBD disappoints

Vedanta's microbiome therapy for ulcerative colitis has failed a phase 2 trial and will be shelved, prompting a 20% cut in workforce.

Nicox plans filings for glaucoma after phase 3 win

Viking felled by dropout rates in oral obesity drug trial

Merck has a $2bn flutter on Skyhawk's RNA platform

Pfizer suffers another hit to its GBT sickle cell portfolio

AI could lead to 'golden age' of antibiotics

Vedanta's microbiome therapy for IBD disappoints

CDC panel votes to scrap hepatitis B birth dose advice

How to meet your physicians where they are online

News

Editor's Picks